{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"23","value":"18.2"},{"groupId":"OG001","lowerLimit":"3","upperLimit":"23","value":"10.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"description":"DoCR is defined as the time from first response (stringent complete response (sCR), complete response (CR)) to the earlier date of progressive disease or death due to any cause.\n\nsCR=complete response plus normal free light chain ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry; CR=negative immunofixation of serum and urine and disappearance of any soft tissue plasmacytomas and \\< 5% plasma cells in bone marrow aspirates.\n\nProgressive disease is defined as (1) Increase of ≥25% from lowest confirmed response; (2) Appearance of a new lesion(s); (3) ≥50% increase in circulating plasma cells.","dispersionType":"Full Range","groups":[{"description":"JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells expansion","id":"OG000","title":"Phase 2 600 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy","id":"OG001","title":"Phase 2a 600 x 10^6 Cells Anti-BCMA"}],"paramType":"MEDIAN","populationDescription":"All participants with sCR or CR who received conforming JCARH125 cell product at the recommended phase 2 dose and have measurable disease at the last disease assessment prior to receiving JCARH125 infusion in phase 2 and in phase 2a","reportingStatus":"POSTED","timeFrame":"From first response to the date of progression or death due to any cause, whichever occurs first (Up to approixmately 61 months)","title":"Duration of Complete Response (DoCR) in Phase 2 and 2a","type":"SECONDARY","unitOfMeasure":"Months"}